ImmunoPrecise Antibodies Ltd. (CVE:IPA) (OTCQB:IPATF) said its subsidiary Talem Therapeutics has entered into a research license agreement with Janssen Research & Development, LLC providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.
Under the agreement, ImmunoPrecise - a global leader in therapeutic antibody discovery and development – said Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed.
READ: ImmunoPrecise Antibodies and its AI collaborator team up on research program to help fight coronavirus
Ilse Roodink, chairwoman of Talem's Scientific Advisory Committee and Scientific Director at ImmunoPrecise Antibodies Europe said: "This Agreement validates Talem's business concept in early antibody discovery and development.”
She added: "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications."
Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/ specialty diseases.
Jennifer Bath, president and CEO of ImmunoPrecise Antibodies added: "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America."
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients.